Junfeng Du

2.0k total citations
56 papers, 1.3k citations indexed

About

Junfeng Du is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Junfeng Du has authored 56 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology, 16 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Junfeng Du's work include Immune Cell Function and Interaction (11 papers), Immune Response and Inflammation (9 papers) and Immune cells in cancer (9 papers). Junfeng Du is often cited by papers focused on Immune Cell Function and Interaction (11 papers), Immune Response and Inflammation (9 papers) and Immune cells in cancer (9 papers). Junfeng Du collaborates with scholars based in China, United States and Zimbabwe. Junfeng Du's co-authors include Xiaofei Shen, Yang Zhao, Wenxian Guan, Ke Cao, Jinpeng Jiang, Gang Chen, Qianyu Wang, Huiyun Cai, Yong Zhao and Chen Wang and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Cell Metabolism.

In The Last Decade

Junfeng Du

53 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Junfeng Du China 18 551 439 315 188 176 56 1.3k
Maya Gulubova Bulgaria 21 499 0.9× 450 1.0× 500 1.6× 205 1.1× 140 0.8× 107 1.5k
Arezoo Gowhari Shabgah Iran 21 547 1.0× 405 0.9× 385 1.2× 104 0.6× 152 0.9× 44 1.3k
Tim Smallie United Kingdom 9 964 1.7× 503 1.1× 233 0.7× 221 1.2× 178 1.0× 9 1.6k
Jingyun Luan China 24 396 0.7× 739 1.7× 217 0.7× 332 1.8× 150 0.9× 36 1.4k
Masashi Shiina Japan 10 469 0.9× 470 1.1× 251 0.8× 111 0.6× 208 1.2× 12 1.3k
Maorong Fu China 3 467 0.8× 553 1.3× 466 1.5× 107 0.6× 179 1.0× 4 1.6k
Zhigang Chen China 21 389 0.7× 590 1.3× 231 0.7× 143 0.8× 259 1.5× 37 1.3k
Rahul Shinde United States 15 647 1.2× 543 1.2× 322 1.0× 97 0.5× 129 0.7× 25 1.5k
Clara Hammarström Norway 17 578 1.0× 387 0.9× 446 1.4× 94 0.5× 162 0.9× 35 1.3k
Gantsetseg Tumurkhuu Japan 20 590 1.1× 651 1.5× 212 0.7× 140 0.7× 144 0.8× 51 1.3k

Countries citing papers authored by Junfeng Du

Since Specialization
Citations

This map shows the geographic impact of Junfeng Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junfeng Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junfeng Du more than expected).

Fields of papers citing papers by Junfeng Du

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junfeng Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junfeng Du. The network helps show where Junfeng Du may publish in the future.

Co-authorship network of co-authors of Junfeng Du

This figure shows the co-authorship network connecting the top 25 collaborators of Junfeng Du. A scholar is included among the top collaborators of Junfeng Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junfeng Du. Junfeng Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Yu, Heng, Hang Jiang, Xiaofeng Lu, et al.. (2024). Analysis of risk factors for liver metastasis in patients with gastric cancer and construction of prediction model: A multicenter study. Discover Oncology. 15(1). 363–363.
3.
Wang, Qianyu, Xiaofei Shen, Xiaopeng Yang, et al.. (2024). Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer. npj Precision Oncology. 8(1). 61–61. 17 indexed citations
4.
Wang, Qianyu, Wentao Zhong, Yi Xiao, et al.. (2024). Pan-immune-inflammation value as a prognostic biomarker for colon cancer and its variation by primary tumor location. World Journal of Gastroenterology. 30(33). 3823–3836. 8 indexed citations
5.
Wang, Qianyu, Xiaofei Shen, Gang Chen, & Junfeng Du. (2023). How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. International Journal of Cancer. 153(4). 709–722. 14 indexed citations
6.
Wu, Zhenhua, Xuanxuan Zhang, Yunhe An, et al.. (2023). CLMP is a tumor suppressor that determines all-trans retinoic acid response in colorectal cancer. Developmental Cell. 58(23). 2684–2699.e6. 5 indexed citations
7.
Zhang, Fei, Huiwen Yan, Liuyang Wang, et al.. (2023). Targeting intratumor heterogeneity suppresses colorectal cancer chemoresistance and metastasis. EMBO Reports. 24(8). e56416–e56416. 14 indexed citations
8.
Zhao, Yang, et al.. (2018). The origins and homeostasis of monocytes and tissue‐resident macrophages in physiological situation. Journal of Cellular Physiology. 233(10). 6425–6439. 112 indexed citations
9.
Zhao, Yang, Xiaofei Shen, Ke Cao, et al.. (2018). Dexamethasone-Induced Myeloid-Derived Suppressor Cells Prolong Allo Cardiac Graft Survival through iNOS- and Glucocorticoid Receptor-Dependent Mechanism. Frontiers in Immunology. 9. 282–282. 52 indexed citations
10.
Shen, Xiaofei, Yang Zhao, Ke Cao, et al.. (2017). Wip1 Deficiency Promotes Neutrophil Recruitment to the Infection Site and Improves Sepsis Outcome. Frontiers in Immunology. 8. 1023–1023. 13 indexed citations
11.
Hu, Xuelian, Peng Wang, Junfeng Du, et al.. (2016). Phosphatase Wip1 Masters IL-17–producing Neutrophil-mediated Colitis in Mice. Inflammatory Bowel Diseases. 22(6). 1316–1325. 13 indexed citations
12.
Du, Junfeng, Xiaofei Shen, Yang Zhao, et al.. (2015). Wip1-Deficient Neutrophils Significantly Promote Intestinal Ischemia/Reperfusion Injury in Mice. Current Molecular Medicine. 15(1). 100–108. 19 indexed citations
13.
Shen, Xiaofei, Junfeng Du, Wenxian Guan, & Yong Zhao. (2014). The balance of intestinal Foxp3+regulatory T cells and Th17 cells and its biological significance. Expert Review of Clinical Immunology. 10(3). 353–362. 20 indexed citations
16.
Du, Junfeng, et al.. (2011). Inhibition of T-Cell Expansion Caused by Inducible Costimulator/B7h Costimulation Blockade in Direct Allorecognition Pathway. Transplantation Proceedings. 43(10). 3960–3963. 6 indexed citations
17.
Yang, Liqin, et al.. (2009). CRYSTALLIZATION KINETICS OF SODIUM SULFATE DECAHYDRATE IN AN MSMPR STIRRED CRYSTALLIZER. SHILAP Revista de lepidopterología. 1 indexed citations
18.
Du, Junfeng, Chiou‐Jye Huang, Baohua Zhou, & SF Ziegler. (2009). Isoform-specific inhibition of RORα-mediated transcriptional activation by human FOXP3. The Journal of Immunology. 182(6). 3937–3937. 21 indexed citations
19.
Du, Junfeng, et al.. (2009). Transferable Cardiac Allograft Acceptance Induced by Transfusion of Donor B Cells With Impaired Inducible Costimulator/B7h Allorecognition. Transplantation Proceedings. 41(5). 1840–1843. 4 indexed citations
20.
Li, Qiuyang, Junfeng Du, Ming Yu, et al.. (2008). Transmission electron microscopy of VX2 liver tumors after high-intensity focused ultrasound ablation enhanced with SonoVue®. Advances in Therapy. 26(1). 117–125. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026